![FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC](https://www.dicardiology.com/sites/default/files/styles/content_feed_large_new/public/Farxiga_1.jpeg?itok=kL1UUsf_)
FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC
Farxiga showed cardiovascular and renal benefit in patients with chronic kidney disease irrespective of cardiovascular disease status
![EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study | Fierce Pharma EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 diabetes study | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1505380578/Farxiga.jpg/Farxiga.jpg?VersionId=YGHZeKKtBkpU9PCGQLQdYHqkUDhFdDKW)